IHAM
ICPT

Integral Health Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Integral Health Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-125,000
Closed -$2.03M – 85
2022
Q1 		$2.03M Buy
125,000
+50,000
+67% +$783K 0.53% 55
2021
Q4 		$1.22M Buy
+75,000
New +$1.26M 0.34% 61

Other funds holding ICPT

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Integral Health Asset Management's ICPT Position: Q2 2022 in Review

Integral Health Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2022, closing a stake of 125,000 shares — an estimated $2.03M sold.

Integral Health Asset Management first reported a position in ICPT in Q4 2021 and held it in 2 quarters. The position peaked at $2.03M in Q1 2022. 144 funds tracked by Wall St. Rank hold ICPT as of Q2 2022.

  • Integral Health Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2022 after selling out during the quarter.
  • Integral Health Asset Management sold 125,000 Intercept Pharmaceuticals, Inc. shares in Q2 2022, an estimated $2.03M.
  • Integral Health Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2021 and held it in 2 quarters.
  • Integral Health Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $2.03M in Q1 2022.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2022.

Based on Integral Health Asset Management's 13F filing for Q2 2022, filed 3 Aug 2022.